Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy in Group E COPD Patients

This study aims to evaluate the efficacy and safety of allogeneic human UC-MSC to treat stage E Chronic Obstructive Pulmonary Disease (COPD). All participants in this study already receive standard treatment for COPD, which includes triple inhaled medications with LABA, LAMA and ICS. We hypothesize that UC-MSCs will improve COPD management. UC-MSCs are prepared in a certified laboratory and given intravenously. For 12 months from day 0, all patients will be observed for comprehensive safety evaluation, pulmonary function testing (PFT), quality of life indicators including questionnaires, 6-min walk test (6MWT), and inflammation biomarkers.

NCT Number	NCT07441226
Lead Sponsor	RSUP Persahabatan Collaborators: PT. Prodia Stem Cell Indonesia
Conditions	Chronic Obstructive Pulmonary Disease (COPD)
Enrollment	20 participants
Start Date	2025-08-08
Primary Completion	2027-12 (estimated)
Study Completion	2028-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-27